COMP <GO>
SOLV vs LLY // EV/EBITDA & P/E VALUATION
Solventum Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: SOLV 3
— LLY 12
▲ EV/EBITDA & P/E VALUATION LEADER: SOLV
LAST: $81.33 (-2.67%) • MKT CAP: $14.22B
valuation
7.3x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SOLV VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SOLV | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 83.64% | -30.14 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.70% | 32.36% | -13.66 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 7.3x | 36.4x | -29.12 | SOLV | /valuation <GO> |
| Free Cash Flow Yield | -0.07% | 2.30% | -2.37 | LLY | /fcf-yield <GO> |
| Operating Margin | 26.20% | 40.21% | -14.01 | LLY | /operating-margins <GO> |
| Net Profit Margin | 18.70% | 31.90% | -13.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 0.90% | 45.51% | -44.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 9.29 | -7.04 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.77% | +0.33 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.3 | 77.9 | -42.63 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 0.51 | +0.55 | SOLV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 26.3x | -17.75 | SOLV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.22B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SOLV REV | LLY REV | SOLV GROSS % | LLY GROSS % | SOLV FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.32B | $65.18B | 53.5% | 83.0% | -$10.0M | $16.81B |
| FY 2024 | $8.25B | $45.04B | 55.6% | 81.3% | $805.0M | $8.82B |
| FY 2023 | $8.20B | $34.12B | 44.0% | 79.3% | $1.55B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SOLV // BETA 1.06
LLY // BETA 0.51